Bupropion

Bupropion is a second-generation, or atypical, antidepressant chemically classified as an aminoketone, structurally distinct from the tricyclic and serotonergic drugs that dominate the field ^[1]. It was invented at Burroughs Wellcome in the late 1960s and first approved in the United States as an antidepressant in the 1980s under the brand name Wellbutrin ^[2]. An early formulation was briefly withdrawn because higher doses were linked to seizures, and it returned with a lower maximum dose and, later, sustained-release and extended-release versions that reduced this risk ^[1].

Bupropion is approved for major depressive disorder, for preventing the seasonal pattern of depression known as seasonal affective disorder, and, as the brand Zyban, for smoking cessation ^[2][3]. In trials it produces remission rates broadly comparable to selective serotonin reuptake inhibitors, and it is often chosen when clinicians want to avoid the sexual side effects and weight gain associated with those drugs ^[3]. It is also combined with naltrexone in a medicine used for weight management, and is used off-label for conditions such as attention-deficit hyperactivity disorder ^[3].

As a stop-smoking aid, bupropion is thought to work partly by easing nicotine withdrawal and partly by blocking nicotinic acetylcholine receptors, dampening the reinforcing effects of nicotine ^[4]. Comparative reviews generally find it effective, though the nicotinic partial agonist varenicline tends to outperform it for maintaining long-term abstinence ^[5].

Bupropion is a prescription medicine and appears on the World Health Organization's List of Essential Medicines. It is sold in immediate-release, sustained-release, and extended-release tablets under names including Wellbutrin, Zyban, and Aplenzin, and in combination products. Its most important safety concern is a dose-related risk of seizures, so maximum doses are capped; other common effects include dry mouth, insomnia, and a modest rise in blood pressure ^[1][3].

The headline risk is a dose-dependent drop in seizure threshold, so it is avoided in people with a seizure disorder, an eating disorder (bulimia or anorexia), or during alcohol and benzo withdrawal. Common sides are insomnia, dry mouth, jitteriness, headache, and lower appetite. It is weight-neutral to slightly slimming and skips the sexual side effects SSRIs are known for. It inhibits CYP2D6, so it can push up levels of other drugs cleared that way.

Bupropion is contraindicated with monoamine oxidase inhibitors; concurrent use or a washout shorter than 14 days risks hypertensive reactions, so MAOIs including linezolid and intravenous methylene blue must be separated by two weeks. It is a potent CYP2D6 inhibitor and raises exposure to CYP2D6 substrates such as many antidepressants (fluoxetine, paroxetine, venlafaxine, tricyclics), atomoxetine, metoprolol, and certain antipsychotics (risperidone, haloperidol), and it can blunt tamoxifen activation.

Bupropion lowers the seizure threshold in a dose-dependent way, so combining it with other threshold-lowering agents (antipsychotics, tramadol, theophylline, systemic steroids) or with abrupt alcohol, benzodiazepine, or barbiturate withdrawal increases seizure risk. Its metabolism runs through CYP2B6, so inducers (ritonavir, efavirenz, carbamazepine) reduce levels while CYP2B6 inhibitors (ticlopidine, clopidogrel) raise them. This is research information, not medical advice.

Checking a whole stack? Run it through interactions + stacks.

Bupropion was synthesized in the late 1960s by chemist Nariman Mehta at Burroughs Wellcome and patented in 1974 as an aminoketone antidepressant with an unusual, non-serotonergic profile. It first reached the United States market in 1985 but was withdrawn the following year after reports of seizures at higher doses, then reintroduced in 1989 with revised dosing that greatly reduced that risk. In 1997 the same molecule was approved under the brand name Zyban as an aid to smoking cessation, and it was later combined with naltrexone in a weight-management product. This layered history has given bupropion an enduring role well beyond its original indication.

Bupropion enjoys a strong reputation as a distinctive antidepressant that fills a niche other drugs cannot, thanks to its low likelihood of causing sexual dysfunction or weight gain. Reviews describe it as superior to placebo and comparable to SSRIs such as escitalopram for major depression, while its activating, dopamine-and-norepinephrine profile appeals to patients troubled by fatigue or low motivation. It is also a genuinely effective smoking-cessation aid, particularly in combination regimens, giving it dual value in clinical practice. Prescribers remain mindful of its dose-dependent seizure risk, but with appropriate dosing it is considered a safe and well-established option, and its favorable side-effect signature keeps it a frequent first choice for the right patient.